Revisiting Inhibition Effects of miR-28 as a Metastasis Suppressor in
Gastrointestinal Cancers

Saiedeh      Razi Soofiyani; Sohrab      Minaei Beirami; Kamran      Hosseini; Mina      Mohammadi Nasr; Maryam      Ranjbar; Haleh      Forouhandeh; Vahideh      Tarhriz; Mohammadreza      Sadeghi
Abstract

MicroRNAs are critical epigenetic regulators that can be used as diagnostic, prognostic, and therapeutic biomarkers for the treatment of various diseases, including gastrointestinal cancers, among a variety of cellular and molecular biomarkers. MiRNAs have also shown oncogenic or tumor suppressor roles in tumor tissue and other cell types. Studies showed that the dysregulation of miR-28 is involved in cell growth and metastasis of gastrointestinal cancers. MiR-28 plays a key role in controlling the physiological processes of cancer cells including growth and proliferation, migration, invasion, apoptosis, and metastasis. Therefore, miR-28 expression patterns can be used to distinguish patient subgroups. Based on the previous studies, miR-28 expression can be a suitable biomarker to detect tumor size and predict histological grade metastasis. In this review, we summarize the inhibitory effects of miR-28 as a metastasis suppressor in gastrointestinal cancers. miR-28 plays a role as a tumor suppressor in gastrointestinal cancers by regulating cancer cell growth, cell differentiation, angiogenesis, and metastasis. As a result, using it as a prognostic, diagnostic, and therapeutic biomarker in the treatment of gastrointestinal cancers can be a way to solve the problems in this field.
Keywords: Circulating miR-28, gastrointestinal cancers, biomarkers, metastasis, epigenetic regulators, MiRNAs.
Graphical Abstract

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin  2019; 69(1): 7-34.

[2]
Sung H FJ, Siegel RL, Laversanne M, Soerjomataram I. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021; 71: 209-49.

[3]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin  2021; 71(1): 7-33.
 [http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]

[4]
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M. Colorectal Carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci  2017; 18(1): 197.
 [http://dx.doi.org/10.3390/ijms18010197] [PMID: 28106826]

[5]
Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol  2014; 20(7): 1635-49.
 [http://dx.doi.org/10.3748/wjg.v20.i7.1635] [PMID: 24587643]

[6]
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res  2018; 10(1179)(1322): 239-48.
 [http://dx.doi.org/10.2147/CMAR.S149619]

[7]
Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M. The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice. Biomed Pharmacother  2017; 95(1950-6007): 1082-90.

[8]
Nahand JS, Taghizadeh-boroujeni S, Karimzadeh M, et al. microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J Cell Physiol  2019; 234(10): 17064-99.
 [http://dx.doi.org/10.1002/jcp.28457] [PMID: 30891784]

[9]
Mei J, Xu R, Hao L, Zhang Y. MicroRNA-613: A novel tumor suppressor in human cancers. Biomed Pharmacother  2020; 123: 109799.
 [http://dx.doi.org/10.1016/j.biopha.2019.109799] [PMID: 31877552]

[10]
Zou X, Zhu D, Zhang H, Zhang S, Zhou X, He X. MicroRNA expression profiling analysis in serum for nasopharyngeal carcinoma diagnosis. Gene  2019; 727(1879-0038)

[11]
Abkhooie L, Sarabi MM, Kahroba H, et al. Potential roles of MyomiRs in cardiac development and related diseases. Curr Cardiol Rev  2021; 17(4): e010621188335.
 [http://dx.doi.org/10.2174/1573403X16999201124201021] [PMID: 33238844]

[12]
Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol  2014; 11(1759-4782): 145-56.
 [http://dx.doi.org/10.1038/nrclinonc.2014.5]

[13]
Zhang Y, Ma Y. Association of microRNA-933 variant with the susceptibility to gastric cancer. J BUON  2017; 22(1107-0625): 390-5.

[14]
Xu J, Jiang N, Shi H, Zhao S, Yao S, Shen H. miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1. Int J Oncol  2017; 50(1791-2423): 1383-91.

[15]
Rizzo MA-O, Berti G, Russo F, Evangelista M, Pellegrini M, Rainaldi G. The miRNA pull out assay as a method to validate the miR-28-5p targets identified in other tumor contexts in prostate cancer. Int J Genomics  2017; 2017(2314-436X)
 [http://dx.doi.org/10.1155/2017/5214806]

[16]
Zhou SL, Hu ZQ, Zhou ZJ, Dai Z, Wang Z, Cao Y. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology  2016; 63(1527-3350): 1560-75.

[17]
Sayagués JM, Corchete LA, Gutiérrez ML, Sarasquete ME, Del Mar Abad M, Bengoechea O. Genomic characterization of liver metastases from colorectal cancer patients. oncotarget  2016; 7(1949-2553): 72908-22.

[18]
Vychytilova-Faltejskova P, Pesta M, Radova L, Liska V, Daum O, Kala Z. Genome-wide microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. Cancer Genomics Proteomics  2016; 13(1790-6245): 311-6.

[19]
Lv YA-O, Yang H, Ma X, Wu G. Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferation, apoptosis, migration and invasion. Cancer Cell Int  2019; 19(1475-2867): 187.
 [http://dx.doi.org/10.1186/s12935-019-0915-x]

[20]
Tsiakanikas P, Kontos CK, Kerimis D, Papadopoulos IN, Scorilas A. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clin Chem Lab Med  2018; 56(1437-4331): 990-1000.
 [http://dx.doi.org/10.1515/cclm-2017-0430]

[21]
Almeida MI. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology  2012; 142(1528-0012): 886-96.

[22]
Liang Z, Gao KP, Wang YX, et al. RNA sequencing identified specific circulating miRNA biomarkers for early detection of diabetes retinopathy. Am J Physiol Endocrinol Metab  2018; 315(3): E374-85.
 [http://dx.doi.org/10.1152/ajpendo.00021.2018] [PMID: 29812988]

[23]
Jia L, Chopp M, Wang L, Lu X, Szalad A, Zhang ZG. Exosomes derived from high‐glucose‐stimulated Schwann cells promote development of diabetic peripheral neuropathy. FASEB J  2018; 32(12): 6911-22.
 [http://dx.doi.org/10.1096/fj.201800597R] [PMID: 29932869]

[24]
Jimenez-Lucena R, Alcala-Diaz JF, Roncero-Ramos I, Lopez-Moreno J, Camargo A, Gomez-Delgado F. MiRNAs profile as biomarkers of nutritional therapy for the prevention of type 2 diabetes mellitus: From the CORDIOPREV study. Clinical nutrition (Edinburgh, Scotland)  2021; 40(3): 1028-38.

[25]
Ji HP, Xiong Y, Song WT, et al. MicroRNA-28 potentially regulates the photoreceptor lineage commitment of Müller glia-derived progenitors. Sci Rep  2017; 7(1): 11374.
 [http://dx.doi.org/10.1038/s41598-017-11112-4] [PMID: 28900179]

[26]
Zhou X, Wen W, Shan X, et al. MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism. Thromb Res  2016; 138: 91-5.
 [http://dx.doi.org/10.1016/j.thromres.2015.12.006] [PMID: 26702486]

[27]
Mao H, Liu L, Hu Y. Mesenchymal stem cells-derived exosomal miRNA-28-3p promotes apoptosis of pulmonary endothelial cells in pulmonary embolism. Eur Rev Med Pharmacol Sci  2020; 24(20): 10619-31.
 [http://dx.doi.org/10.21203/rs.3.rs-36047/v1] [PMID: 33155220]

[28]
Zhu RY, Zhang D, Zou HD, Zuo XS, Zhou QS, Huang H. MiR-28 inhibits cardiomyocyte survival through suppressing PDK1/Akt/mTOR signaling. In Vitro Cell Dev Biol Anim  2016; 52(10): 1020-5.
 [http://dx.doi.org/10.1007/s11626-016-0065-6] [PMID: 27338735]

[29]
Liu J, Liu XQ, Liu Y, et al. MicroRNA 28-5p regulates ATP-binding cassette transporter A1 via inhibiting extracellular signal-regulated kinase 2. Mol Med Rep  2016; 13(1): 433-40.
 [http://dx.doi.org/10.3892/mmr.2015.4563] [PMID: 26718613]

[30]
Torres-Do Rego A, Barrientos M, Ortega-Hernández A, et al. Identification of a plasma microrna signature as biomarker of subaneurysmal aortic dilation in patients with high cardiovascular risk. J Clin Med  2020; 9(9): 2783.
 [http://dx.doi.org/10.3390/jcm9092783] [PMID: 32872191]

[31]
Zhao X, Wang S, Sun W. Expression of miR-28-3p in patients with Alzheimer’s disease before and after treatment and its clinical value. Exp Ther Med  2020; 20(3): 2218-26.
 [http://dx.doi.org/10.3892/etm.2020.8920] [PMID: 32765698]

[32]
Wang X, Liu J, Zhou L, Ho WZ. Morphine withdrawal enhances HIV infection of macrophages. Front Immunol  2019; 10: 2601.
 [http://dx.doi.org/10.3389/fimmu.2019.02601] [PMID: 31803178]

[33]
Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med  2007; 13(10): 1241-7.
 [http://dx.doi.org/10.1038/nm1639] [PMID: 17906637]

[34]
Meng L, Yang H, Jin C, Quan S. miR-28-5p suppresses cell proliferation and weakens the progression of polycystic ovary syndrome by targeting prokineticin-1. Mol Med Rep  2019; 20(3): 2468-75.
 [http://dx.doi.org/10.3892/mmr.2019.10446] [PMID: 31322191]

[35]
Xu Y, Li Y. MicroRNA-28-3p inhibits angiotensin-converting enzyme 2 ectodomain shedding in 293T cells treated with the spike protein of severe acute respiratory syndrome coronavirus 2 by targeting A disintegrin and metalloproteinase 17. Int J Mol Med  2021; 48(4): 189.
 [http://dx.doi.org/10.3892/ijmm.2021.5022] [PMID: 34414454]

[36]
Eadon MT, Jacob A, Cunningham PN, Quigg RJ, Garcia JGN, Alexander JJ. Transcriptional profiling reveals that C5a alters microRNA in brain endothelial cells. Immunology  2014; 143(3): 363-73.
 [http://dx.doi.org/10.1111/imm.12314] [PMID: 24801999]

[37]
Kaur H, Sehgal R, Kumar A, Sehgal A, Bansal D, Sultan AA. Screening and identification of potential novel biomarker for diagnosis of complicated Plasmodium vivax malaria. J Transl Med  2018; 16(1): 272.
 [http://dx.doi.org/10.1186/s12967-018-1646-9] [PMID: 30286756]

[38]
Prats-Puig A, Ortega FJ, Mercader JM, et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab  2013; 98(10): E1655-60.
 [http://dx.doi.org/10.1210/jc.2013-1496] [PMID: 23928666]

[39]
Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer  2011; 47(2): 163-74.
 [http://dx.doi.org/10.1016/j.ejca.2010.11.005] [PMID: 21145728]

[40]
Wong RSY. Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res  2011; 30(1): 87.
 [http://dx.doi.org/10.1186/1756-9966-30-87] [PMID: 21943236]

[41]
Green DR. Means to an end: apoptosis and other cell death mechanisms. Cold Spring Harbor Laboratory Press 2011.

[42]
Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther  2016; 1(1): 15004.
 [http://dx.doi.org/10.1038/sigtrans.2015.4] [PMID: 29263891]

[43]
Zhang L, Wang X, Liu X, et al. miR-28-5p targets MTSS1 to regulate cell proliferation and apoptosis in esophageal cancer. Acta Biochim Biophys Sin  2020; 52(8): 842-52.
 [http://dx.doi.org/10.1093/abbs/gmaa059] [PMID: 32645138]

[44]
Wu W, He K, Guo Q, et al. SSRP1 promotes colorectal cancer progression and is negatively regulated by miR‐28‐5p. J Cell Mol Med  2019; 23(5): 3118-29.
 [http://dx.doi.org/10.1111/jcmm.14134] [PMID: 30762286]

[45]
Ma ML, Zhang HY, Zhang SY, Yi XL. LncRNA CDKN2B-AS1 sponges miR-28-5p to regulate proliferation and inhibit apoptosis in colorectal cancer. Oncol Rep  2021; 46(4): 213.
 [http://dx.doi.org/10.3892/or.2021.8164] [PMID: 34368874]

[46]
Zhu G, Wang Z, Mijiti M, Du G, Li Y, Dangmurenjiafu G. MiR-28-5p promotes human glioblastoma cell growth through inactivation of FOXO1. Int J Clin Exp Pathol  2019; 12(8): 2972-80.
 [PMID: 31934134]

[47]
Luan XF, Wang L, Gai XF. The miR‐28‐5p‐CAMTA2 axis regulates colon cancer progression via Wnt/β‐catenin signaling. J Cell Biochem  2021; 122(9): 945-57.
 [http://dx.doi.org/10.1002/jcb.29536] [PMID: 31709644]

[48]
Li Y, Zhao W, Ni J, et al. Predicting the value of adjuvant therapy in esophageal squamous cell carcinoma by combining the total number of examined lymph nodes with the positive lymph node ratio. Ann Surg Oncol  2019; 26(8): 2367-74.
 [http://dx.doi.org/10.1245/s10434-019-07489-3] [PMID: 31187360]

[49]
Liu K, Zhao T, Wang J, et al. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer. Cancer Lett  2019; 458: 21-8.
 [http://dx.doi.org/10.1016/j.canlet.2019.05.018] [PMID: 31125642]

[50]
Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol  2021; 18(6): 432-43.
 [http://dx.doi.org/10.1038/s41575-021-00419-3] [PMID: 33603224]

[51]
Xie SH, Lagergren J. Risk factors for oesophageal cancer. Best Pract Res Clin Gastroenterol  2018; 36-37: 3-8.
 [http://dx.doi.org/10.1016/j.bpg.2018.11.008] [PMID: 30551854]

[52]
Xie F, Ye L, Chen J, et al. The impact of Metastasis Suppressor-1, MTSS1, on oesophageal squamous cell carcinoma and its clinical significance. J Transl Med  2011; 9(1): 95.
 [http://dx.doi.org/10.1186/1479-5876-9-95] [PMID: 21696600]

[53]
Huang Z, Zhang L, Zhu D, et al. A novel serum microRNA signature to screen esophageal squamous cell carcinoma. Cancer Med  2017; 6(1): 109-19.
 [http://dx.doi.org/10.1002/cam4.973] [PMID: 28035762]

[54]
Liu SG, Qin XG, Zhao BS, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett  2013; 5(5): 1639-42.
 [http://dx.doi.org/10.3892/ol.2013.1251] [PMID: 23761828]

[55]
Wei L, Sun J, Zhang N, et al. Noncoding RNAs in gastric cancer: Implications for drug resistance. Mol Cancer  2020; 19(1): 62.
 [http://dx.doi.org/10.1186/s12943-020-01185-7] [PMID: 32192494]

[56]
Eyvazi S, Vostakolaei MA, Dilmaghani A, et al. The oncogenic roles of bacterial infections in development of cancer. Microb Pathog  2020; 141: 104019.
 [http://dx.doi.org/10.1016/j.micpath.2020.104019] [PMID: 32006638]

[57]
Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: An evolving issue. Eur J Surg Oncol  2016; 42(1): 18-27.
 [http://dx.doi.org/10.1016/j.ejso.2015.10.016] [PMID: 26632080]

[58]
Wang C, Wu C, Yang Q, et al. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B. Oncotarget  2016; 7(45): 73888-902.
 [http://dx.doi.org/10.18632/oncotarget.12516] [PMID: 27729617]

[59]
Schneider C, Setty M, Holmes AB, et al. microRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA  2014; 111(22): 8185-90.
 [http://dx.doi.org/10.1073/pnas.1322466111] [PMID: 24843176]

[60]
Li L, Zhu X, Shou T, et al. MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway. Mol Med Rep  2018; 17(3): 4003-10.
 [PMID: 29257342]

[61]
Guo Y, Cui X, Zhang Y, Ma X, Ren A, Huang H. Diagnostic and prognostic value of serum miR-296-5p and miR-28-3p in human gastric cancer. Cancer Biother Radiopharm 2020.
 [http://dx.doi.org/10.1089/cbr.2020.4144] [PMID: 32898433]

[62]
Jeddi F, Alipour S, Najafzadeh N, et al. Reduced Levels of miR–28 and miR–200a act as predictor biomarkers of aggressive clinicopathological characteristics in gastric cancer patients. Galen Med J  2019; 8: 1329.
 [http://dx.doi.org/10.31661/gmj.v8i0.1329] [PMID: 34466494]

[63]
Xiao F, Cheng Z, Wang P, et al. MicroRNA-28-5p inhibits the migration and invasion of gastric cancer cells by suppressing AKT phosphorylation. Oncol Lett  2018; 15(6): 9777-85.
 [http://dx.doi.org/10.3892/ol.2018.8603] [PMID: 29928352]

[64]
Yue CF, Li LS, Ai L, Deng JK, Guo YM. sMicroRNA-28-5p acts as a metastasis suppressor in gastric cancer by targeting Nrf2. Exp Cell Res  2021; 402(2): 112553.
 [http://dx.doi.org/10.1016/j.yexcr.2021.112553] [PMID: 33737068]

[65]
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol  2020; 72(2): 250-61.
 [http://dx.doi.org/10.1016/j.jhep.2019.08.025] [PMID: 31954490]

[66]
Ferenci P, Fried M, Labrecque D, et al. Hepatocellular Carcinoma (HCC). J Clin Gastroenterol  2010; 44(4): 239-45.
 [http://dx.doi.org/10.1097/MCG.0b013e3181d46ef2] [PMID: 20216082]

[67]
Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer  2017; 1868(2): 564-70.
 [http://dx.doi.org/10.1016/j.bbcan.2017.10.002] [PMID: 29054475]

[68]
Han T, Xiang DM, Sun W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol  2015; 63(3): 651-60.
 [http://dx.doi.org/10.1016/j.jhep.2015.03.036] [PMID: 25865556]

[69]
Li XF, Chen C, Xiang DM, et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology  2017; 66(6): 1934-51.
 [http://dx.doi.org/10.1002/hep.29372] [PMID: 28714104]

[70]
Sun C, Shui B, Zhao W, et al. Central role of IP3R2-mediated Ca2+ oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor. Cell Death Dis  2019; 10(6): 396.
 [http://dx.doi.org/10.1038/s41419-019-1613-2] [PMID: 31113961]

[71]
Xia Q, Han T, Yang P, et al. MicroRNA-28-5p regulates liver cancer stem cell expansion via IGF-1 pathway. Stem Cells Int  2019; 2019: 1-16.
 [http://dx.doi.org/10.1155/2019/8734362] [PMID: 31885628]

[72]
Shi X, Teng F. Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). Mol Cell Biochem  2015; 408(1-2): 283-93.
 [http://dx.doi.org/10.1007/s11010-015-2506-z] [PMID: 26160280]

[73]
Han Q, Li J, Xiong J, Song Z. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression. J Exp Clin Cancer Res  2020; 39(1): 151.
 [http://dx.doi.org/10.1186/s13046-020-01660-5] [PMID: 32771045]

[74]
Liu Y, Guo C, Li F, Wu L. LncRNA LOXL1‐AS1/miR‐28‐5p/SEMA7A axis facilitates pancreatic cancer progression. Cell Biochem Funct  2020; 38(1): 58-65.
 [http://dx.doi.org/10.1002/cbf.3449] [PMID: 31732974]

[75]
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin  2020; 70(3): 145-64.
 [http://dx.doi.org/10.3322/caac.21601] [PMID: 32133645]

[76]
Jeon J, Du M, Schoen RE, et al. Determining risk of colorectal cancer and starting age of screening based on lifestyle, environmental, and genetic factors. Gastroenterology  2018; 154(8): 2152-2164.e19.
 [http://dx.doi.org/10.1053/j.gastro.2018.02.021] [PMID: 29458155]

[77]
Fillon M. Study aims to improve colorectal cancer screening rates. CA Cancer J Clin  2019; 69(3): 161-3.
 [http://dx.doi.org/10.3322/caac.21472] [PMID: 30861095]

[78]
Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, featuring survival. J Natl Cancer Inst  2017; 109(9)
 [http://dx.doi.org/10.1093/jnci/djx030] [PMID: 28376154]

[79]
Choi Y, Sateia HF, Peairs KS, Stewart RW. Screening for colorectal cancer. Semin Oncol  2017; 44(1): 34-44.
 [http://dx.doi.org/10.1053/j.seminoncol.2017.02.002] [PMID: 28395761]

[80]
Xie H, Guo JH, An WM, et al. Diagnostic value evaluation of trefoil factors family 3 for the early detection of colorectal cancer. World J Gastroenterol  2017; 23(12): 2159-67.
 [http://dx.doi.org/10.3748/wjg.v23.i12.2159] [PMID: 28405143]

[81]
Li J, Li K, Xie M, Tang Y, Tang Y, Hu B. Clinical significance and prognostic value of miR-28-5p in colon cancer. Dis Markers  2020; 2020: 1-11.
 [http://dx.doi.org/10.1155/2020/3159831] [PMID: 32566038]

[82]
Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut  2017; 66(1): 70-8.
 [http://dx.doi.org/10.1136/gutjnl-2015-309800] [PMID: 26408641]

[83]
Zhou T, Wu L, Ma N, et al. SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9. Cell Death Dis  2020; 11(12): 1071.
 [http://dx.doi.org/10.1038/s41419-020-03273-4] [PMID: 33318478]

[84]
Liu CL, Zang XX, Huang H, et al. The expression of B7-H3 and B7-H4 in human gallbladder carcinoma and their clinical implications. Eur Rev Med Pharmacol Sci  2016; 20(21): 4466-73.
 [PMID: 27874953]

[85]
Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ tregs in gastric cancer and its clinical significance. Int J Clin Oncol  2015; 20(2): 273-81.
 [http://dx.doi.org/10.1007/s10147-014-0701-7] [PMID: 24804867]

[86]
Soofiyani SR, Hosseini K, Soleimanian A, et al. An overview on the role of miR-451 in lung cancer: Diagnosis, therapy, and prognosis. MicroRNA  2021; 10(3): 181-90.
 [http://dx.doi.org/10.2174/2211536610666210910130828] [PMID: 34514995]

[87]
Sun J, Chen L, Zhang G, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother  2010; 59(8): 1163-71.
 [http://dx.doi.org/10.1007/s00262-010-0841-1] [PMID: 20333377]

[88]
Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø. B7-H3 expression in colorectal cancer: Associations with clinicopathological parameters and patient outcome. BMC Cancer  2014; 14(1): 602.
 [http://dx.doi.org/10.1186/1471-2407-14-602] [PMID: 25139714]

[89]
Wang L, Zhao Y, Xu M, Zhou F, Yan J. Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer. J BUON  2019; 24(3): 1120-7.

[90]
Lone SN, Maqbool R, Parray FQ, Ul Hussain M. Triose‐phosphate isomerase is a novel target of miR‐22 and miR‐28, with implications in tumorigenesis. J Cell Physiol  2018; 233(11): 8919-29.
 [http://dx.doi.org/10.1002/jcp.26821] [PMID: 29856481]

[91]
Cui M, Chen M, Shen Z, Wang R, Fang X, Song B. LncRNA‐UCA1 modulates progression of colon cancer through regulating the miR‐28‐5p/HOXB3 axis. J Cell Biochem  2019; 120(5): 6926-36.
 [http://dx.doi.org/10.1002/jcb.27630] [PMID: 30652355]
Cite As
MicroRNA

Revisiting Inhibition Effects of miR-28 as a Metastasis Suppressor in Gastrointestinal Cancers

Abstract

Graphical Abstract
